San Francisco Bay Area Pliant Therapeutics Inc. announces it has dosed the first cohort of subjects in a Phase I clinical trial evaluating the safety, tolerability and pharmacodynamics, and pharmacokinetics of anti-fibrotic agent PLN-74809. This investigational drug is being tested for treatment of patients with idiopathic pulmonary fibrosis, a disease with very poor prognosis and few impactful treatment options.

Source: PR Newswire

Pin It on Pinterest